ALLO – allogene therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Days Volatility
Open
Prior Close

YTD

1 Day

ALLO

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

9/30

08:30 am

allo

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Low Report

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Report

9/26

08:30 am

allo

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

Low Report

Report

9/6

01:08 pm

allo

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]

Low Report

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]

Report

8/26

11:41 pm

allo

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies [Seeking Alpha]

Medium Report

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies [Seeking Alpha]

Report

8/15

08:34 am

allo

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

Neutral Report

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

Report

8/10

12:58 am

allo

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript [Seeking Alpha]

Low Report

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript [Seeking Alpha]

Report

8/9

07:04 pm

allo

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Citigroup Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.

Low Report

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Citigroup Inc. from $7.00 to $8.00. They now have a "buy" rating on the stock.

Report

8/9

09:11 am

allo

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $14.00 price target on the stock, down previously from $17.00.

Low Report

Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $14.00 price target on the stock, down previously from $17.00.

Report

Date

Time

Symbol

Company Name

Action

%Chg

8/7/2024

04:02 pm

allo

allogene therapeutics, inc.

IN-LINE Report

-4.5%

allogene therapeutics, inc.

Report

5/13/2024

04:01 pm

allo

allogene therapeutics, inc.

BEAT Report

2.1%

allogene therapeutics, inc.

Report

3/14/2024

04:05 pm

allo

allogene therapeutics, inc.

MISS Report

1.3%

allogene therapeutics, inc.

Report

11/2/2023

04:02 pm

allo

allogene therapeutics, inc.

BEAT Report

16.7%

allogene therapeutics, inc.

Report

Date

Time

Action

From

Firm

Impact

%Chg

8/15

08:34 am

Reiterates

Buy

HC Wainwright

Report

0.0%

Report

8/9

06:49 pm

Maintains

Buy

Citigroup

Low

Report

1.7%

Report

8/9

06:49 pm

Maintains

Buy

Citigroup

Low

Report

1.7%

Report

8/8

10:16 am

Assumes

Outperform

Oppenheimer

Medium

Report

-4.3%

Report

8/8

10:16 am

Assumes

Outperform

Oppenheimer

Medium

Report

-4.3%

Report

8/8

09:03 am

Initiates

Outperform

Oppenheimer Holdings Inc.

Medium

Report

-5.2%

Report

8/8

07:31 am

Maintains

Buy

Canaccord Genuity

Medium

Report

-4.5%

Report

Date

Time

Symbol

Headline

Impact

10/7

04:28 pm

allo

Form 8-K Allogene Therapeutics, For: Oct 03

Medium Report

Form 8-K Allogene Therapeutics, For: Oct 03

Report

8/23

04:15 pm

allo

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Medium Report

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Report

8/21

04:19 pm

allo

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Medium Report

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Report

8/7

04:08 pm

allo

Form 10-Q Allogene Therapeutics, For: Jun 30

Medium Report

Form 10-Q Allogene Therapeutics, For: Jun 30

Report

8/7

04:05 pm

allo

Form 8-K Allogene Therapeutics, For: Aug 07

Medium Report

Form 8-K Allogene Therapeutics, For: Aug 07

Report

Stock Stats

News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings

Order Stats
Sub-Penny

Odd lot

Avg. bid-ask spread

Avg. bid-ask size

Shares at ask/bid

Off exchange

Main News & Impact Reports

Don’t Miss Out On The Next BIG Stock Move

Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.